Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET): One Single Center, Safety and Feasibility Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Shenyang, China, 110016
- Recruiting
- Department of Neurology, General Hospital of Northern Theater Command
-
Contact:
- Hui-Sheng Chen, Ph.D.
- Phone Number: +86 13352452086
- Email: chszh@aliyun.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years;
- Acute ischemic stroke patients who is eligible for endovascular treatment;
- Signed informed consent.
Exclusion Criteria:
- Modified Rankin Score >2 caused by a history of prior stroke;
- Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (<80000/mm3);
- Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
- Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);
- Unsuitable for this clinical studies assessed by researcher.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intra-arterial administration of 3-n-butylphthalide
Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min.
|
Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of server adverse events
Time Frame: 48 hours
|
server adverse events including femoral artery dissection, local thrombosis, seudoaneurysm, arteriovenousfistula, etc.
|
48 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of symptomatic intracranial hemorrhage (sICH)
Time Frame: 48 hours
|
sICH was defined as 4 or more increase in NIHSS caused by hemorrhage
|
48 hours
|
|
Proportion of patients with modified Rankin Score 0 to 1
Time Frame: 90 days
|
Proportion of patients with modified Rankin Score 0 to 1
|
90 days
|
|
Proportion of patients with modified Rankin Score 0 to 2
Time Frame: 90 days
|
Proportion of patients with modified Rankin Score 0 to 2
|
90 days
|
|
Modified Rankin Score
Time Frame: 90 days
|
Modified Rankin Score
|
90 days
|
|
Decrease in national institutes of health stroke scale (NIHSS)
Time Frame: 48 hours
|
Decrease in NIHSS scoring at 48 hours after the treatment
|
48 hours
|
|
Proportion of intraparenchymal hemorrhage (PH1 and PH2)
Time Frame: 48 hours
|
Proportion of intraparenchymal hemorrhage (PH1 and PH2) within 48 hours after the treatment
|
48 hours
|
|
Changes in cerebral edema
Time Frame: 48 hours
|
Cerebral edema was determined by cerebral volume or midline shift
|
48 hours
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in serum factors levels and blood gas in diverse vessel region
Time Frame: Hour 0
|
Differences in serum factors levels and blood gas in diverse vessel region
|
Hour 0
|
|
Changes in serum factors levels
Time Frame: 30 minutes, 24 hours
|
changes in serum factors levels before and at different timepoints after recanalization
|
30 minutes, 24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- K (2020) 32
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.